Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.

被引：0
|
作者：
May, Michael S.
Wooster, Margaux
May, Benjamin
Shu, Catherine A.
Henick, Brian S.
Stoopler, Mark
Smith-Marrone, Stephanie
Saqi, Anjali
Mansukhani, Mahesh M.
Riely, Gregory J.
Hershman, Dawn L.
Herzberg, Benjamin
机构：
[1] Columbia Univ Med Ctr, New York, NY USA
[2] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA
[3] Columbia Univ, Irving Med Ctr, New York, NY USA
[4] NYP Columbia, Bronxville, NY USA
[5] Columbia Univ, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11012
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis
    Luo, Wei
    Zhu, Jing
    Zhang, Wenxue
    Yu, Airu
    Zhou, Wei
    Xu, Ke
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1295 - 1303
  • [32] The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRASG12C inhibitor adagrasib in KRASG12C non-small cell lung carcinoma
    Patel, Hetika V.
    Smith, Alison
    Chan, Stacia
    Kessler, Linda
    Burrows, Francis
    Malik, Shivani
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [33] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Torres-Jimenez, Javier
    Espinar, Javier Baena
    de Cabo, Helena Bote
    Berjaga, Maria Zurera
    Esteban-Villarrubia, Jorge
    Fraile, Jon Zugazagoitia
    Paz-Ares, Luis
    DRUGS, 2024, 84 (05) : 527 - 548
  • [34] KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer
    Cai, Chang
    Yao, Shuo
    Zou, Yanmei
    Lu, Hui
    Chen, Xiuqiong
    Wang, Yali
    Zheng, Kun
    Zhu, Feng
    Wang, Yihua
    Xiong, Hua
    Zhu, Junfei
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (12) : 1637 - 1652
  • [35] On the impact of KRASG12D subtype non-small cell lung cancer
    Lopez, Sandra
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [36] The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
    Liu, Yan
    Li, Hui
    Zhu, Jing
    Zhang, Yang
    Liu, Xianhong
    Li, Rixin
    Zhang, Qiang
    Cheng, Ying
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2447 - 2454
  • [37] Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases
    Kommalapati, Anuhya
    Mansfield, Aaron S.
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3179 - 3181
  • [38] Barriers to non-small cell lung cancer trial eligibility
    Hardesty, Jeffrey J.
    Kanarek, Norma F.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2018, 9 : 45 - 49
  • [39] Adagrasib in KRYSTAL-12 has Broken the KRASG12C Enigma Code in Non-Small Cell Lung Carcinoma
    Luo, Faustine X.
    Arter, Zhaohui Liao
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 161 - 167
  • [40] Synergistic enhancement of KRASG12C inhibitor adagrasib by AMD1 inhibitor SAM486 in non-small cell lung cancer: in vitro and in vivo studies
    Lopez-Munoz, R.
    Martin-Martin, A.
    Buelvas, N.
    Guzman-Kunstmann, S.
    Chipon, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S87 - S87
12345